Thursday, November 05, 2026
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
3Q26 Reported With Start Of OCU410 Phase 2/3 Trial. Ocugen reported a loss of $3.6 million, or $(0.01) per share, including a non-cash gain of $16.6 million from Change In Fair Value of Derivatives. Without this gain, Net Loss would have been $20.2 million, or $(0.06) per share. This adjusted Net Loss is consistent with previous quarters and our estimates for 3Q26. Cash and equivalents were $84.6 million as of September 30, 2026, which we expect to fund operations through 2028.
OCU400 In Retinitis Pigmentosa. The Phase 3 liMeliGhT (pronounced Limelight) trial continues, with data expected to be announced in 1Q2027. The Process Performance Qualification (PPQ) batches for the CMC section of the BLA have been completed. As discussed in our Research Note on September 28, the Bahamas has granted Provisional Approval and Priority Designation for OCU400. We continue to expect submission of the BLA to the FDA and an MAA in Europe, with approval later in FY2027.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
